Overview of implantable and injectable biomaterials in immunotherapy

Prerana  Prakash; Pushpa  Agrawal; AH Manjunatha  Reddy

doi:10.30574/gscbps.2021.16.1.0208

Authors

Prerana Prakash Department of Biotechnology RV College of Engineering, Bangalore-560-059, Karnataka, India.
Pushpa Agrawal Department of Biotechnology RV College of Engineering, Bangalore-560-059, Karnataka, India.
AH Manjunatha Reddy Department of Biotechnology RV College of Engineering, Bangalore-560-059, Karnataka, India.

DOI:

https://doi.org/10.30574/gscbps.2021.16.1.0208

Keywords:

Immunotherapy, Implantable biomaterial, Injectable biomaterial, Hydrogels, Colony stimulating factors (CSFs)

Abstract

Immunotherapy has shown promising applications in cancer treatment as it boosts the systemic immune response. Existing immunotherapy strategies have certain drawbacks which can be addressed by engineered biomaterials. In this review, we focused on advanced immunotherapy methods involving implantable and injectable biomaterials for the treatment of cancer. Engineered biomaterials as carriers for immunomodulatory agents aid in the local drug delivery, thus reducing the frequency of off-target side effects. Also, biomaterial-based cancer vaccines have the potential to target specific tissues by finely altering the physical properties of the drug to achieve desired drug release kinetics

Metrics

Metrics Loading ...

References

Fergal J. O'Brien. Biomaterials & scaffolds for tissue engineering. Materials Today. 2011; 14(3): 88-95.

Langer R, Vacanti JP. Tissue engineering. Science. 1993; 260(5110): 920-926.

Salgado AJ, Coutinho OP, Rui L, Reis RL. Bone tissue engineering: State of the art and future trends. Macromolecular Bioscience. 2004; 4: 743-765.

A Dolcimascolo, G Calabrese, S. Conoci, R Parenti. Innovative Biomaterials for Tissue Engineering. Biomaterial-supported Tissue Reconstruction or Regeneration. 2019.

Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials, 2000; 175-189.

Kowalski P, Bhattacharya C, Afewerki S, Langer R. Smart Biomaterials: Recent Advances and Future Directions. ACS Biomaterials Science & Engineering. 2018; 4(11): 3809-3817.

Anderson J. M, Rodriguez A, Chang D. T. Foreign Body Reaction to Biomaterials. Semin. Immunol. 2008; 20 (2): 86–100.

Wick G, Grundtman C, Mayerl C, Wimpissinger T.F, Feichtinger J, Zelger B, Sgonc R. Wolfram D. The Immunology of Fibrosis. 2013; 31.

Singh A, Peppas NA, Hydrogels and scaffolds for immunomodulation. Adv Mater. Oct 2014; 26(38): 6530-41.

Hotaling NA, Tang L, Irvine DJ, Babensee JE; Biomaterial Strategies for Immunomodulation. Annu Rev Biomed Eng. 2015; 17: 317-49.

Mehta NK, Moynihan KD, Irvine DJ. Engineering New Approaches to Cancer Vaccines. Cancer Immunol Res. Aug 2015; 3(8): 836-43.

Leach, D. G., Young, S., & Hartgerink, J. D. Advances in immunotherapy delivery from implantable and injectable biomaterials. Acta biomaterialia. 2019; 88: 15–31.

Carr EJ, Dooley J, Garcia-Perez JE. The cellular composition of the human immune system is shaped by age and cohabitation. Nat Immunol. 2016; 17(4): 461-468.

Jones JD, Vance RE, Dangl JL. Intracellular innate immune surveillance devices in plants and animals. Science. 2016; 354(6316).

Irvine DJ. Materializing the future of vaccines and immunotherapy. Nat Rev Mater. 2016; 1(1): 1-2.

Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016; 164(6): 1233-1247

Papaioannou NE, Beniata OV, Vitsos P, et al. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016; 4(14): 241.

Ribas A. releasing the brakes on cancer immunotherapy. N Engl J Med. 2015; 373(16): 1490- 1492.

Cousin-Frankel J; cancer immunotherapy; Science. 2013; 342(6165): 1432-1433.

Klevorn LE, Teague RM. Adapting cancer immunotherapy models for the real world. Trends Immunol. 2016; 37(6): 354- 363.

Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016; 16(9): 566-581.

Goldberg MS. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell. 2015; 161(2): 201-204.

Ali OA, Verbeke C, Johnson C, et al. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res. 2014; 74(6): 1670-1681.

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382): 1350- 1355.

Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016; 22(12): 1402- 1410.

Ishihara J, Fukunaga K, Ishihara A, et al. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017; 9(415): eaan 0401.

Curran KJ, Silverman LB, Kobos R, et al. Chimeric antigen receptor T cells for cancer immunotherapy. J Clin Oncol. 2015; 33(15): 1703- 1706.

Wang C, Ye Y, Hochu GM, et al. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 2016; 16(4): 2334- 2340.

Tsao CT, Kievit FM, Ravanpay A, et al. Thermoreversible poly (ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy. Biomacromolecules. 2014; 15(7): 2656- 2662.

Kelly SH, Shores LS, Votaw NL, Collier JH. Biomaterial strategies for generating therapeutic immune responses. Adv Drug Deliv Rev. 2017; 114: 3- 18.

Vishwakarma A, Bhise NS, Evangelista MB, et al. engineering immunomodulatory biomaterials to tune the inflammatory response. Trends Biotechnol. 2016; 34(6): 470- 482.

Hu X, Wu T, Bao Y, Zhang ZJ. Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. J Control Release. 2017; 256: 26- 45.

Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1): 20- 37.

Wang C, Wen D, Gu Z. Cellular bioparticulates with therapeutics for cancer immunotherapy. Bioconjugate Chem. 2017; 29(3): 702- 708.

Iang W, Von Roemeling CA, Chen Y, et al. Designing nanomedicine for immuno-oncology. Nat Biomed Eng. 2017; 1(2): 1- 11.

Cai L, Xu J, Yang Z, Tong R, Dong Z, Wang C, & Leong K. W. Engineered biomaterials for cancer immunotherapy. MedComm. 2020.

Leach DG, Young S, Hartgerink JD. Advances in immunotherapy delivery from implantable and injectable biomaterials. Acta Biomater. 2019; 88: 15- 31.

Koshy ST, Mooney DJ. Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol. 2016; 40: 1- 8.

Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4): 265- 277.

Ali OA, Huebsch N, Cao L, et al. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009; 8(2): 151- 158.

Zhang C, Zhang J, Shi G, et al. A light responsive nanoparticle-based delivery system using pheophorbide a graft polyethylenimine for dendritic cell-based cancer immunotherapy. Mol. Pharmaceutics. 2017; 14(5): 1760- 1770.

Myron S, Teck Chuan L, Injectable biomaterials: a perspective on the next wave of injectable therapeutics, Biomed. Mater. 2016; 1(1): 014110.

Bencherif SA, Sands RW, Bhatta D, Arany P, Verbeke CS, Edwards DA, Mooney DJ. Injectable preformed scaffolds with shape-memory properties. 2012; 109(48): 19590–19595.

Bencherif SA, Sands RW, Ali OA, Li WA, Lewin SA, Braschler TM, Shih T-YS, Verbeke CS, Bhatta D, Dranoff G, Mooney DJ. Injectable cryogel-based whole cell cancer vaccines. Nat. Commun. 2015; 6: 7556

Duong HTT, Thambi T, Yin Y, et al. Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma. Biomaterials. 2020; 230: 119599.

Ercan H, Durkut S, Koc-Demir A, Elçin AE, Elçin YM. Clinical Applications of Injectable Biomaterials. Adv Exp Med Biol. 2018; 1077: 163-182.

Zhang L, Zhou J, Hu L, et al. In situ formed fibrin scaffold with cyclophosphamide to synergize with immune checkpoint blockade for inhibition of cancer recurrence after surgery. Adv Funct Mater. 2020; 30(7): 1906922.

Kim J, Li WA, Choi Y, Lewin SA, Verbeke CS, Dranoff G, Mooney DJ, Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy, Nat. Biotechnol. 2014; 33(64).

Chen Q, Wang C, Zhang X, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2019; 14(1): 89- 97.